Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Controlled, Open-Label, Phase 2 Study of Cemiplimab as a Single Agent and in Combination With RP1 in Patients With Advanced Cutaneous Squamous Cell Carcinoma

Next Previous
Trial Profile

A Randomized, Controlled, Open-Label, Phase 2 Study of Cemiplimab as a Single Agent and in Combination With RP1 in Patients With Advanced Cutaneous Squamous Cell Carcinoma

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 29 Jan 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cemiplimab (Primary) ; Vusolimogene oderparepvec (Primary)
  • Indications Carcinoma; Skin cancer; Squamous cell cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms CERPASS
  • Sponsors Replimune

Most Recent Events

  • 12 Nov 2024 According to a Replimune media release, R& D expenses were $43.4 million for the fiscal second quarter ended September 30, 2024, as compared to $49.1 million for the fiscal second quarter ended September 30, 2023. This decrease was primarily due to the wind down of the CERPASS and IGNYTE Phase II studies, as well as the deprioritization of development efforts on RP3.
  • 05 Dec 2023 According to a Replimune media release, trial will continue as planned to assess DOR, progression free survival (PFS) and overall survival (OS) with greater maturity.
  • 05 Dec 2023 Primary endpoint (Complete Response Rate (CRR) according to blinded independent review) has not been met, according to a Replimune media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top